Hansa Biopharma AB (publ) (HNSA) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the HANSA Biopharma Quarter 3 2025 Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touchtone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Hansa Biopharma CEO, Renée Aguiar-Lucander. Please go ahead. Thank you very much, Operator. Good afternoon, good morning. Welcome to the Hansa Biopharma conference called Review Q3 and results for the first nine months of 2025. I'm Renée Aguiar-Lucander, CEO for Hansa Biopharma, and joining me today is Evan Ballantyne, CFO, Richard Philipson, Chief Medical Officer, and Maria Torrenson, Chief Operating Officer and President of the U.S. Please turn to slide two. Please allow me to just quickly draw your attention to the fact that we will be making forward-looking statements during the presentation, and you should therefore apply appropriate caution. Please turn to page three and today's agenda. Today we'll discuss the progress we've made in the nine months of 2025 and review the quarterly performance. I'll also share my reflections and insights based on my first six months in the role. The presentation itself should take roughly 20 minutes, after which there will be an opportunity to ask questions during a Q&A session. Please turn to page four. Over the past several months, Hansa has been through quite a transformation. including a significant reshaping of the capital structure involving debt restructuring and significant strengthening of the cash ...